RNase 7 participates in cutaneous innate control of Corynebacterium amycolatum

Stephanie Walter, Franziska Rademacher, Nicole Kobinger, Maren Simanski, Regine Gläser & Jürgen Harder

Nondiphtheriae corynebacteria are abundant members of the normal microbiota of human healthy skin and mucosal surfaces. It is known that aerobic corynebacteria contribute to axillary malodor by biotransformation of sweat components. There are various reports demonstrating that nondiphtheria corynebacteria are also able to cause various infections such as skin and soft tissue infections, granulomatous lymphadenitis, pneumonitis, pharyngitis and endocarditis, especially in immunocompromised patients.

Corynebacterium amycolatum has been originally isolated from human skin as a normal member of the cutaneous microbiota. Although C. amycolatum is a normal inhabitant of human skin there is increasing evidence that C. amycolatum has the capacity to act as an opportunistic pathogen causing skin and soft tissue infections. C. amycolatum has also been associated with wound infections and surgical site infections. This suggests that the normal presence of C. amycolatum on the skin surface should be tightly controlled.

Antimicrobial peptides (AMP) are known for their potential to control the growth of microorganisms on the skin surface. Since the interaction of AMP with corynebacteria has not yet been investigated we sought to determine whether AMP may play a role to control the growth of corynebacteria. RNase 7 is an important skin-derived AMP abundantly expressed by keratinocytes. Its broad spectrum of antimicrobial activity together with its abundance in the uppermost epidermal layers indicates that RNase 7 plays an important role in cutaneous innate defense. However, there are no reports available exploring the interaction of corynebacteria with human keratinocytes and RNase 7.

Here we show an epidermal growth factor receptor (EGFR)-dependent induction of RNase 7 in primary keratinocytes stimulated with C. amycolatum. In addition, C. amycolatum induced RNase 7 also in a 3D skin equivalent. We further demonstrate that RNase 7 exhibits antimicrobial activity against corynebacteria and contributes to the capacity of human stratum corneum to control the growth of C. amycolatum. These data show for the first time that corynebacteria are able to activate human keratinocytes and identify RNase 7 as an important mediator to control the growth of corynebacteria on the skin surface.
Results

*Corynebacterium amycolatum* induces RNase 7 expression in keratinocytes and in an organotypic 3D skin equivalent. Stimulation of human primary keratinocytes with living *C. amycolatum* induced RNase7 gene expression as measured by real-time PCR. ELISA analyses revealed also an increased secretion of RNase 7 by keratinocytes upon stimulation with living *C. amycolatum*. An organotypic skin equivalent was treated with living *C. amycolatum* for 22–24 h. RNase7 gene expression was analyzed by real-time PCR and RNase 7 secretion was determined by a RNase 7-specific ELISA of the culture medium.

Induction of RNase 7 by *Corynebacterium amycolatum* in keratinocytes requires functional EGFR. Several reports indicate that the EGFR is critically involved in the induction of RNase 7 by microorganisms. Therefore we sought to determine whether the induction of RNase 7 by *C. amycolatum* was also dependent on the EGFR. To this end we incubated the keratinocytes with the selective EGFR inhibitor AG-1478. As shown in Fig. 1a, AG-1478 diminished the induction of RNase7 gene expression and protein secretion in keratinocytes treated with *C. amycolatum*. In line with these experiments the use of EGFR-blocking antibody cetuximab also significantly decreased the *C. amycolatum*-mediated RNase7 gene and protein expression in...
Figure 2. C. amycolatum-induced RNase 7 expression in keratinocytes is mediated by the epidermal growth factor receptor (EGFR). Human primary keratinocytes were treated for 24 h with living C. amycolatum with or without the selective EGFR inhibitor AG-1478 (10 μM). (a) Relative RNase7 gene expression was analyzed by real-time PCR and (b) RNase 7 protein secretion was measured by analysis of the supernatant using an RNase 7 specific ELISA. In a second experimental setup stimulation of the keratinocytes with living C. amycolatum was done for 24 h in the absence or presence of the EGFR blocking antibody cetuximab (20 μg/ml). (c) Relative RNase7 gene expression was analyzed by real-time PCR and (d) RNase 7 protein secretion was measured by analysis of the supernatant using an RNase 7-specific ELISA. Shown are means ± s.e.m. of nine separate stimulations (*p < 0.05; **p < 0.01, one-way analysis of variance ANOVA using Tukey's multiple comparison test). (e) Analysis of RNase 7 expression by immunostaining in a 3D skin equivalent. The 3D skin equivalent was left unstimulated or stimulated with living C. amycolatum for 24 h in the presence or absence of cetuximab (20 μg/ml). Bars represent 50 μM.
primary keratinocytes (Fig. 2c,d). Immunohistochemistry analysis of a 3D skin equivalent stimulated with living *C. amycolatum* revealed that the *C. amycolatum*-mediated RNase 7 induction was inhibited by treatment with cetuximab (Fig. 2e).

**Figure 3.** RNase 7 exhibits antimicrobial activity against *C. amycolatum* and *C. xerosis*. (a) *C. amycolatum* and (b) *C. xerosis* were incubated with the indicated concentrations of RNase 7 in 10 mM sodium phosphate buffer (pH 7.4) containing 1% BHI and 0.05% BSA. After 3 h incubation time samples were serial diluted and plated on BHI agar plates. The colony forming units (CFU) were counted after overnight incubation at 37 °C. (c) The antimicrobial activity of wildtype recombinant RNase 7 (R7) and ribonuclease-deficient recombinant RNase 7 (R7mut) were tested at the indicated concentrations against *C. amycolatum*. Data are means of three independent experiments (**p < 0.01; ***p < 0.001, one-way analysis of variance ANOVA using Tukey’s multiple comparison test).

**RNase 7 exhibits antimicrobial activity against *C. amycolatum* and *C. xerosis.** To determine whether RNase 7 is able to restrict the growth of corynebacteria we incubated *C. amycolatum* and *C. xerosis* with different concentrations of RNase 7 in a microdilution assay for 3 h. As shown in Fig. 3a, b RNase 7 dose-dependently inhibited the growth of *C. amycolatum* and *C. xerosis*. Concentrations lower than 1 µg/ml RNase 7 still inhibited the growth of the bacteria. To investigate whether the enzymatic activity of RNase 7 is necessary for the observed killing activity we used a mutated recombinant RNase 7 without ribonuclease activity. This ribonuclease-inactive RNase 7 variant showed similar activity against *C. amycolatum* as compared to recombinant wild-type RNase 7 (Fig. 3c) indicating that the ribonuclease activity of RNase 7 is not crucial for its antibacterial activity against *C. amycolatum*.

**RNase 7 contributes to the antimicrobial activity of human stratum corneum against *C. amycolatum*.** To analyze the functional importance of RNase 7 in cutaneous defense against corynebacteria we used an RNase 7 blocking antibody which neutralized the antimicrobial activity of RNase 7 against *C. amycolatum* whereas an irrelevant control antibody had no influence (Fig. 4a). We then incubated a stratum corneum extract with *C. amycolatum* in the presence of the RNase 7 blocking antibody or in the presence of the irrelevant antibody. The stratum corneum extract was able to control the growth of *C. amycolatum* also in the presence of the irrelevant control antibody. In contrast, inactivation of RNase 7 in the stratum corneum extract by incubation with the RNase 7 blocking antibody led to an outgrowth of *C. amycolatum* (Fig. 4b). These data show that RNase 7 contributes to the capacity of human stratum corneum to control the growth of *C. amycolatum*. 
RNase 7 is an antimicrobial protein which is abundantly expressed in keratinocytes and characterized by a broad spectrum of antimicrobial activity. This suggests that RNase 7 may play a major role in cutaneous defense. This is in concordance with recent functional studies reporting that RNase 7 contributes to the capacity of the human skin surface to inhibit the growth of *P. aeruginosa* and *S. aureus*, *E. faecium* and *Staphylococcus epidermidis*. This is in line with these observations it has been reported that high levels of RNase 7 may confer protection against *S. aureus* infection of the skin. Since there is increasing evidence that AMP may also play an important role to control and shape the commensal microbiota, inhabitants of healthy normal skin. Our data show that RNase 7 exhibits potent antimicrobial activity against *C. amycolatum* and *C. xerosis*. The use of a recombinant ribonuclease-deficient RNase 7 mutant revealed that the enzymatic activity of RNase 7 was dispensable for its antimicrobial activity against *C. amycolatum*. This is in line with our previous study documenting that the activity of RNase 7 against the gram-positive bacterium *Enterococcus faecium* required no ribonuclease activity.

Our data revealed that concentrations lower than 1 µg/ml RNase 7 already restricted the growth of the corynebacteria suggesting that RNase 7 may play an important role to control the growth of corynebacteria on the skin surface. In support of this hypothesis our results show that the capacity of stratum corneum to inhibit the growth of *S. aureus*, *E. faecium* and *P. aeruginosa* is associated with the presence of RNase 7, which may help to control cutaneous growth of corynebacteria, inhabitants of healthy normal skin. Our data show that RNase 7 exhibits potent antimicrobial activity against *C. amycolatum* and *C. xerosis*. The use of a recombinant ribonuclease-deficient RNase 7 mutant revealed that the enzymatic activity of RNase 7 was dispensable for its antimicrobial activity against *C. amycolatum*. This is in line with our previous study documenting that the activity of RNase 7 against the gram-positive bacterium *Enterococcus faecium* required no ribonuclease activity.

As mentioned above corynebacteria are abundant commensals on the skin surface. Another abundant skin commensal is *Staphylococcus epidermidis*. Wanke *et al.* reported that *S. epidermidis* induced the expression of RNase 7 in keratinocytes and this induction required functional EGFR. One may speculate that a permanent induction of RNase 7 by skin commensals such as coagulase-negative staphylococci and corynebacteria may increase cutaneous defense by providing constant antimicrobial activity on the skin surface. A failure to adequately induce RNase 7 may contribute to the increased cutaneous infection risk of cancer patients receiving anti-EGFR therapy.

Taken together, our data indicate a novel role of RNase 7 to control the growth of corynebacteria on human skin. It remains to be shown whether a failure to adequately control the growth of *C. amycolatum* and other cutaneous corynebacteria may be associated with a higher risk for infections caused by these bacteria. In addition, it is an intriguing hypothesis that variations in the expression of corynebacteria-controlling AMP such as RNase 7 may influence body odor formation.

**Discussion**

RNase 7 is an antimicrobial protein which is abundantly expressed in keratinocytes and characterized by a broad spectrum of antimicrobial activity. This suggests that RNase 7 may play a major role in cutaneous defense. This is in concordance with recent functional studies reporting that RNase 7 contributes to the capacity of the human skin surface to inhibit the growth of *S. aureus*, *E. faecium* and *P. aeruginosa*. In line with these observations, it has been reported that high levels of RNase 7 may confer protection against *S. aureus* infection of the skin. Since there is increasing evidence that AMP may also play an important role to control and shape the commensal microbiota, inhabitants of healthy normal skin. Our data show that RNase 7 exhibits potent antimicrobial activity against *C. amycolatum* and *C. xerosis*. The use of a recombinant ribonuclease-deficient RNase 7 mutant revealed that the enzymatic activity of RNase 7 was dispensable for its antimicrobial activity against *C. amycolatum*. This is in line with our previous study documenting that the activity of RNase 7 against the gram-positive bacterium *Enterococcus faecium* required no ribonuclease activity.

Our data revealed that concentrations lower than 1 µg/ml RNase 7 already restricted the growth of the corynebacteria suggesting that RNase 7 may play an important role to control the growth of corynebacteria on the skin surface. In support of this hypothesis, our results show that the capacity of stratum corneum to inhibit the growth of *S. aureus*, *E. faecium* and *P. aeruginosa* is associated with the presence of RNase 7, which may help to control cutaneous growth of corynebacteria, inhabitants of healthy normal skin. Our data show that RNase 7 exhibits potent antimicrobial activity against *C. amycolatum* and *C. xerosis*. The use of a recombinant ribonuclease-deficient RNase 7 mutant revealed that the enzymatic activity of RNase 7 was dispensable for its antimicrobial activity against *C. amycolatum*. This is in line with our previous study documenting that the activity of RNase 7 against the gram-positive bacterium *Enterococcus faecium* required no ribonuclease activity.

As mentioned above corynebacteria are abundant commensals on the skin surface. Another abundant skin commensal is *Staphylococcus epidermidis*. Wanke *et al.* reported that *S. epidermidis* induced the expression of RNase 7 in keratinocytes and this induction required functional EGFR. One may speculate that a permanent induction of RNase 7 by skin commensals such as coagulase-negative staphylococci and corynebacteria may increase cutaneous defense by providing constant antimicrobial activity on the skin surface. A failure to adequately induce RNase 7 may contribute to the increased cutaneous infection risk of cancer patients receiving anti-EGFR therapy.

Taken together, our data indicate a novel role of RNase 7 to control the growth of corynebacteria on human skin. It remains to be shown whether a failure to adequately control the growth of *C. amycolatum* and other cutaneous corynebacteria may be associated with a higher risk for infections caused by these bacteria. In addition, it is an intriguing hypothesis that variations in the expression of corynebacteria-controlling AMP such as RNase 7 may influence body odor formation.
Methods

Cell culture and stimulation. Primary normal human keratinocytes (NHEK, Promocell, Heidelberg, Germany) were cultured in “Keratinocyte Growth Medium 2” (KGM2) and seeded in 12-well plates for stimulation (passage 3–5). Cells used for stimulation were always 100% confluent. Corynebacterium amylolactum and Corynebacterium xerosis (clinical isolates from the Institute of Infection Medicine, Kiel; identity verified by MALDI-TOF mass spectrometry (MALDI Biotyper, Bruker, Billerica, MA)) were cultured in brain-heart infusion (BHI) medium (Sigma-Aldrich, St. Louis, MO). For stimulation an overnight culture of bacteria grown at 37 °C under agitation was pelleted by centrifugation (2000 × g, 5 min), washed with phosphate buffered saline (PBS, Biowest SAS, Nuaille, France) and resuspended and diluted in KGM2 to an optical density (OD600) of 0.2 and further diluted 1:10 in KGM2 cell culture medium for stimulation. Stimulation (500 µl each well) was carried out for 20–24 h or for the indicated time period. To analyze the impact of the EGFR a specific monoclonal anti-EGFR antibody cetuximab (20 µg/ml, Merck, Darmstadt, Germany) as well as the specific EGFR inhibitor AG-1478 (10 µM, Tyrophostin, ENZO LifeScience, Lörrach, Germany) were used.

Organotypic 3D skin equivalent. The organotypic 3D skin equivalent was generated as previously described14. The 3D skin equivalent was stimulated with 20 µl C. amylolactum diluted in KGM2 (OD600 of 0.2) as described above. In order to block the EGFR 20 µg/ml cetuximab was added to the culture medium in the external wells 45 min before stimulation. After stimulation for 24 h two biopsies were taken from each 3D skin equivalent using a 6 mm biopsy punch. One biopsy was embedded in paraffin for immunohistochemical analysis and the other biopsy was used for RNA isolation. The KGM2 medium in the external wells was harvested for ELISA.

RNA isolation and cDNA synthesis. Total RNA of the keratinocytes and the 3D skin equivalent was isolated using 500 µl of the RNA isolation reagent Crystal RNAmagic according to the manufacturer’s protocol (Biolab Products, Göttingen, Germany). The isolated RNA was dissolved in H2O and 0.5 µg total RNA was reversely transcribed to cDNA using an oligo (DT)18 primer and 50 Units Maxima Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA) according to the supplier’s protocol.

Real-time PCR analysis. Quantitative real-time PCR was done in a StepOnePlus Real Time PCR System (Applied Biosystem, Carlsbad, CA) as previously described24 using SYBR Premix Ex Taq II (TaKaRa Bio, Saint-Germain-en-Laye, France) and cDNA corresponding to 10 ng total RNA as template. The following intron-spanning primers were used: RNase 7: 5′-GGA GTC ACA GCA CGA AGA CCA-3′ (forward primer) and 5′-CAT GCC TGA GTT GCA TGC TTT A-3′ (reverse primer) and the housekeeping gene RPL38 (ribosomal protein L38): 5′-TCA AGG ACT TCC TGC TCA CA-3′ (forward primer) and 5′-AAA GGT ATC TGC TGC ATC GAA-3′ (reverse primer). Standard curves were generated for each primer pair using serial dilutions of template cDNA. Relative RNase7 gene expression is given as a ratio between expression of RNase7 and RPL38 gene expression.

ELISA. Secreted RNase 7 protein levels in the cell culture supernatants were measured by a specific RNase 7 ELISA as previously described45. The detection range of the RNase 7 ELISA was between 0.3 ng/ml and 40.0 ng/ml.

Immunostaining. The organotypic 3D skin equivalent was embedded in paraffin and immunostained as performed as described36. Briefly, a self-generated goat anti-RNase 7 antibody13 was used followed by biotinylated rabbit anti-goat IgG antibody (DakoCytomation, Glostrup, Denmark) and avidin/biotinylated enzyme complex (Vectastain ABC-AP staining-kit, Vector laboratories, Peterborough, UK) and a red alkaline phosphatase sub-

Antimicrobial Assay. Corynebacteria were grown in H2O medium overnight at 37 °C until reaching an OD600 of 0.2. This culture was diluted 1:1000 in 10 mM sodium phosphate buffer containing 2% BHI medium and 0.1% BSA (bovine serum albumin, Sigma-Aldrich). 25 µl of this bacteria solution was mixed with 25 µl 10 mM sodium phosphate buffer containing different concentrations of recombinant RNase 7 or stratum corneum extract prepared as previously described37. The use of human stratum corneum derived from the heel was approved by the Ethics Committee at the Medical Faculty of the Christian-Albrechts-University, Kiel, Germany (A104/06) in concordance with the Declaration of Helsinki protocols and donors have given informed consent. Incubation was carried out at 37 °C for 3 h followed by plating serial dilutions on BHI agar plates to analyze colony forming units (CFU) after overnight incubation at 37 °C. In some experiments incubation was performed in the presence of a specific RNase 7 blocking antibody (0.5–0.1 mg/ml) or an irrelevant antibody as described13,14. To investigate whether the ribonuclease activity of RNase 7 is responsible for its antibacterial activity against C. amylolactum we used a recombinant mutant RNase 7 without ribonuclease activity as previously described13.

Data Availability. The datasets generated during the current study are available from the corresponding author on reasonable request.

References
1. Barzantny, H., Brune, I. & Tauch, A. Molecular basis of human body odour formation: insights deduced from corynebacterial genome sequences. International journal of cosmetic science 34, 2–11, https://doi.org/10.1111/j.1468-2494.2011.00669.x (2012).
2. Rudresh, S. M. Non Diphtheritic Corynebacteria: An Emerging Nosocomial Pathogen in Skin and Soft Tissue Infection. Journal of clinical and diagnostic research: ICDR 9, DC19–21, https://doi.org/10.7860/JCDR/2015/15580.6977 (2015).
3. O’Dell, M. L. Skin and wound infections: an overview. American family physician 57, 2424–2432 (1998).
4. Lipsky, B. A., Goldberger, A. C., Tompkins, L. S. & Plorde, J. J. Infections caused by nondiphtheria corynebacteria. Reviews of infectious diseases 4, 1220–1235 (1982).
5. Young, V. M., Meyers, W. F., Moody, M. R. & Schimpff, S. C. The emergence of coryneform bacteria as a cause of nosocomial infections in compromised hosts. Am J Med 70, 646–650 (1981).
6. Collins, M. D., Burton, R. A. & Jones, D. Corynebacterium Amycolatum Sp–Nov a New Mycolic Acid-Less Corynebacterium Species from Human-Skin. Fems Microbiology Letters 49, 349–352 (1988).
7. Olender, A. & Letowska, I. Wound infections due to opportunistic corynebacterium species. Medycyna doswiadczeniowa i mikrobiologia 62, 135–140 (2010).
8. Rizvi, M. et al. Emergence of coryneform bacteria as pathogens in nosocomial surgical site infections in a tertiary care hospital of North India. Journal of infection and public health 6, 283–288, https://doi.org/10.1016/j.jiph.2013.01.005 (2013).
9. Harder, J., Schröder, J. M. & Gläser, R. The skin surface as antimicrobial barrier: present concepts and future outlooks. Exp Dermatol 22, 1–5, https://doi.org/10.1111/exd.12046 (2013).
10. Kopfnagel, V., Harder, J. & Werfel, T. Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions. Current opinion in allergy and clinical immunology 13, 531–536, https://doi.org/10.1097/ACI.0b013e328364ddfd (2013).
11. Takahashi, T. & Gallo, R. L. The Critical and Multifunctional Roles of Antimicrobial Peptides in Dermatology. Dermatologic clinicals 35, 39–50, https://doi.org/10.1016/j.det.2016.07.006 (2017).
12. Harder, J. & Schröder, J. M. RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem 277, 46779–46784 (2002).
13. Köten, B. et al. RNase 7 contributes to the cutaneous defense against Enterococcus faecium. PLoS One 4, e6424, https://doi.org/10.1371/journal.pone.0006424 (2009).
14. Rademacher, F., Simanski, M., Schröder, L., Muldner, M. & Harder, J. The role of RNase 7 in innate cutaneous defense against Pseudomonas aeruginosa. Exp Dermatol 26, 227–233, https://doi.org/10.1111/exd.13166 (2017).
15. Simanski, M., Köten, B., Schröder, J. M., Gläser, R. & Harder, J. Antimicrobial RNases in cutaneous disease. Journal of innate immunity 4, 241–247, https://doi.org/10.1119/0003350299 (2012).
16. Rademacher, F., Simanski, M. & Harder, J. RNase 7 in Cutaneous Defense. International journal of molecular sciences 17, https://doi.org/10.3390/ijms17040560 (2016).
17. Simanski, M., Dressel, S., Gläser, R. & Harder, J. RNase 7 protects healthy skin from Staphylococcus aureus colonization. J Invest Dermatol 130, 2836–2838, https://doi.org/10.1038/jid.2010.217 (2010).
18. Zanger, P. et al. Constitutive expression of the antimicrobial peptide RNase 7 is associated with Staphylococcus aureus infection of the skin. J Infect Dis 200, 1907–1915, https://doi.org/10.1086/648408 (2009).
19. Firat, Y. H. et al. Infection of Keratinocytes with Trichophyton rubrum Induces Epidermal Growth Factor-Dependent RNase 7 and Human Beta-Defensin-3 Expression. PLoS One 9, e93941, https://doi.org/10.1371/journal.pone.0093941 (2014).
20. Lichtenberger, B. M. et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 5, 199ra111, https://doi.org/10.1126/scitranslmed.3005886 (2013).
21. Wanke, I. et al. Skin commensals amplify the innate immune response to pathogens by activation of distinct signaling pathways. J Invest Dermatol 131, 382–390, https://doi.org/10.1038/jid.2010.328 (2011).
22. Gomez, M. I., Seaghdha, M. O. & Prince, A. S. Recognition of Corynebacterium pseudodiphtheriticum by Toll-like receptors and up-regulation of antimicrobial peptides in human corneal epithelial cells. Virulence 7, 616–721, https://doi.org/10.1080/21505594.2015.1066063 (2015).
23. Roy, S., Marla, S. & Praneetha, D. C. Recognition of Corynebacterium pseudodiphtheriticum by Toll-like receptors and up-regulation of antimicrobial peptides in human corneal epithelial cells. Virulence 7, 616–721, https://doi.org/10.1080/21505594.2015.1066063 (2015).
24. Eilers, R. E. Jr. et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. Journal of the National Cancer Institute 102, 47–53, https://doi.org/10.1093/jnci/djp439 (2010).
25. Roth, S. A., Simanski, M., Rademacher, F., Schröder, L. & Harder, J. The Pattern Recognition Receptor NOD2 Mediates Staphylococcus aureus-Induced IL-17C Expression in Keratinocytes. J Invest Dermatol 134, 374–380, https://doi.org/10.1038/jid.2013.313 (2014).
26. Laudien, M., Dressel, S., Harder, J. & Gläser, R. Differential expression pattern of antimicrobial peptides in nasal mucosa and secretion. Rhinology 49, 107–111, https://doi.org/10.4193/Rhino10.036 (2011).

Acknowledgements
We thank Cornelia Wilgus and Heilwig Hinrichs for excellent technical assistance. This study was supported by a grant from the German Research Foundation (DFG) to J.H. (HA 3386/6-1).

Author Contributions
S.W, F.R. and N.K. performed most of the experiments and contributed equally to this work. F.R., M.S. and R.G. conceived and supervised experiments, analyzed data and helped to write the manuscript. J.H. initiated the project, designed the experiments, analyzed and interpreted the results and wrote the final manuscript with input from all authors.

Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017